3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
5
Unknown
3
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
2
Endocrine
2
Conditions
Neoplasms
474
Carcinoma, Non-Small-Cell Lung
449
Breast Neoplasms
331
Neoplasm Metastasis
243
Colorectal Neoplasms
214
Melanoma
213
Leukemia, Myeloid, Acute
191
Multiple Myeloma
180
Recurrence
169
Ovarian Neoplasms
169
Prostatic Neoplasms
163
Lymphoma, Non-Hodgkin
149
Lung Neoplasms
134
Pancreatic Neoplasms
125
Lymphoma
124
Carcinoma, Renal Cell
112
Leukemia, Lymphocytic, Chronic, B-Cell
111
Squamous Cell Carcinoma of Head and Neck
110
Stomach Neoplasms
92
Carcinoma, Hepatocellular
89
Lymphoma, Large B-Cell, Diffuse
88
Leukemia
88
Triple Negative Breast Neoplasms
86
Lymphoma, Follicular
82
Head and Neck Neoplasms
79
Glioblastoma
75
Myelodysplastic Syndromes
70
Urinary Bladder Neoplasms
68
Small Cell Lung Carcinoma
64
Precursor Cell Lymphoblastic Leukemia-Lymphoma
55
Interventions
donafenib
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
INDUSTRY
×
Differentiated Thyroid Cancer
×
Clear all
NCT03602495
2021-12-13
DTC
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3
Terminated
204 enrolled
NCT01843062
2019-08-28
ASTRA
AstraZeneca
Phase 3
Terminated
233 enrolled
14 charts